Results 241 to 250 of about 730,667 (367)
Unraveling Novel Genetic Determinants of Thiopurine Response Via TWAS
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Thiopurines such as 6‐mercaptopurine (6MP) are essential in ALL maintenance therapy. However, dose‐limiting toxicities can significantly disrupt treatment. While genetic variants in TPMT and NUDT15 are known to affect thiopurine response, many patients with normal function ...
Carlotta Bidoli +5 more
wiley +1 more source
Does the Single Nucleotide Polymorphism rs2228145 in IL6R Truly Reflect IL-6 Signaling in Mendelian Randomization Studies? [PDF]
Zhu M, Cao M, Lin L.
europepmc +1 more source
Toll-Like Receptor 7 Single Nucleotide Polymorphism Associated with Hepatitis C Virus Infection, Correlation with HCV Outcome [PDF]
Azza Z. Labeeb, Eman Badr
openalex +1 more source
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety.
Alex J. Coulter +4 more
wiley +1 more source
Clinical study of single nucleotide polymorphism-based chromosome microarray analysis in the etiological diagnosis of fetal congenital heart disease. [PDF]
Zheng Y, Xue S, Ding G, Zhang L, Ding G.
europepmc +1 more source
High‐dose methotrexate for pediatric cancer treatment is frequently associated with mucositis, which can lead to delayed or discontinued treatment and impact survival. While individual genetic variants have been implicated, the cumulative impact of genetic variation within relevant biological pathways remains unexplored.
Xiao Yu Cindy Zhang +9 more
wiley +1 more source
Utilization of single nucleotide polymorphism array in prognostication of cutaneous melanocytic tumor with CRTC1::TRIM11 fusion. [PDF]
Humen S, Khan A, Weston G.
europepmc +1 more source
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park +22 more
wiley +1 more source

